{"links":{"html":"https://www.erudio.com/reports/dewi-nct06059495","json":"https://www.erudio.com/reports/dewi-nct06059495.json","markdown":"https://www.erudio.com/reports/dewi-nct06059495.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"dewi-06059495"}},"request":"https://www.erudio.com/contact?report=dewi-06059495"},"offer":{"cited_commentary_sources":10,"verified_hcp_statements":18,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"dewi-nct06059495"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=dewi-06059495","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/dewi-nct06059495","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T20:21:38.542905Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the sample findings. The page names the trial's tested drugs (dostarlimab) and indication (localized dMMR/MSI-H gastric/GEJ adenocarcinoma)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Clinical complete response (cCR)"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":1,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":2,"title":"Practice change and possible high-surgical-risk exceptions"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":2,"title":"Response verification, residual risk and safe selection"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"Options for patients without cCR"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":4,"title":"Rectal-cancer precedent and other organ-preservation approaches"}],"counts":{"cited_sources":10,"claims_by_expression_type":{"comparison":2,"interpretation":7,"opinion":1,"question":3,"restatement":2,"uncertainty":3},"claims_by_kind":{"source_observation":18},"clinician_statements":10,"evidence_units":18,"findings":4,"organisational_accounts":2,"people_cited":9,"people_identity_verified":9,"people_total":10,"screened_sources":32,"verified_claims":18},"findings_index":[{"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"A possible high-surgical-risk exception is not a general practice change"},{"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Confidence in complete response and its durability remains a condition of surgery avoidance"},{"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":6,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Strong enthusiasm for upper-GI organ preservation coexists with a qualified rectal-cancer analogy"},{"id":"F4","structure":{"claims":3,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Patients without cCR prompt an unanswered radiotherapy question and interest in alternative checkpoint regimens"}],"medical_affairs_question":"What response-validation, durability and safety evidence would justify selective surgery avoidance, including in patients at high surgical risk?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A proposed exception is not routine adoption"},{"id":"section-2","level":2,"title":"A complete clinical response still requires validation and time"},{"id":"section-3","level":2,"title":"Why enthusiasm is strong—and why the rectal analogy has limits"},{"id":"section-4","level":2,"title":"What to do without cCR remains an open question"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T1","label":"Primary endpoint: Clinical complete response (cCR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T20:21:38.542905Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T20:32:11Z","record_hash":"b5607bb5c53cb68d7c37feb34e71f43209e8a938aa2d5ac43c5f2cd3f1b64633","release_hash":"509caccbe1d2ad613bc4783cce6c5872fc873d416de674d92c3054b6e0a4e790","report_id":"erudio-nct06059495","run_id":"2b108aa4-1b80-4c21-ae36-cee10b3ccbba","schema_version":"5.0","slug":"dewi-06059495","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"DEWI asks whether dostarlimab can support watch-and-wait instead of surgery in localized dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma. One X poster welcomes the possibility of organ preservation but treats surgery omission as conditional rather than automatic. That poster questions confidence in complete response and its durability, leaving safe patient selection unresolved. The sources reviewed for this edition place DEWI’s phase II first-interim results at ESMO 2026.","meta_description":"32 sources screened · 18 verified statements (10 from clinicians verified by NPI or staff page) from 10 sources · 4 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-775304e843bdfb1ba1b0","claim-f6b13f5381b6c1e95ea9"],"id":"F1","paraphrase":"An X post asks whether surgery should remain the default following a complete response to immunotherapy in DEWI.","source_channel":"x_thread","source_date":"2026-10-23","title":"A possible high-surgical-risk exception is not a general practice change"},{"cited_claim_ids":["claim-f6f0701a5b88ed2aa20c","claim-72735fd0816fc29fead2"],"id":"F2","paraphrase":"X posts ask about verifying a complete response and whether surgery can be avoided with dostarlimab in DEWI.","source_channel":"x_thread","source_date":"2026-10-23","title":"Confidence in complete response and its durability remains a condition of surgery avoidance"}]},"publication":{"approved_at":"2026-10-29T20:32:11Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T22:21:17Z","summary":"Corrected to match the delivered report: the sample findings. The page names the trial's tested drugs (dostarlimab) and indication (localized dMMR/MSI-H gastric/GEJ adenocarcinoma)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":32},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This is not a complete survey of public discussion or clinician opinion. Some potentially relevant passages were not fully assessed, one discussion was unavailable, and unnamed references or alternative spellings may be missing.","No trial-specific results publication or protocol was available for direct comparison. A dostarlimab regulatory label was also unavailable; these sources do not establish approved use.","The cited 24-patient first-interim analysis and 43-patient summary have different denominators and follow-up. Their juxtaposition does not establish a change in efficacy over time.","Reports of no relapse or death concern the specified complete responders at the stated follow-up. They should not be generalized to all treated patients or interpreted as cure.","Repeated abstract information, reposts, institutional wording and a linked article summary are not additional independent HCP opinions.","One author is unnamed; that author's clinical role is not established in the sources reviewed for this edition. Credentials described by sources for some other authors are not independently confirmed clinical roles."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":10,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-10-25","start":"2026-10-20"},"retrieval_snapshot":"2026-10-29T19:32:06.166923Z","timeline":[{"count":10,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06059495:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06059495:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47eyg4sm7lvqbke5glkahofa-3mykpnmrmc22a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-55hvllkzremivzpssnamt43q-3mwar7wqlws2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-55hvllkzremivzpssnamt43q-3mxetblkgb22n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3myhfs6b3dr2k","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7519046534290931714","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:903843","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879537495890661810:9f78bc49-b5ce-48cb-9418-e505e1c6d5c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102432534395306414:2bfa35cd-db10-4521-9e9f-8e5ab3a8f038","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104356268454686951:b359d6e5-399d-40a5-8f52-05cb4f96eb63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105990928217334044:c005e9b7-687f-4ccb-8337-1162e1a8d6a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108478573388398607:a49fa46f-8d26-4e0b-8440-dedf077c7225","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110607787776745536:d02580f1-82d4-40a3-b92b-82849085c040","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112245552372920408:fc3132a8-61e5-486a-86b4-6843cc1ecf86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112481273423782337:7560f319-c15c-46f3-bf13-82a6c568b514","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112902368220287215:f730ae81-aa09-487b-9d1c-337436f579c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113178581404721160:1546ad19-7311-4d16-8bea-e1f5f49f2f38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113183365482582197:101f3def-dced-4c98-b9fb-edfafefc4d5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113208955425984822:d6849bc3-a98e-4a9a-9b10-335399bba83b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113229637576696292:8fbc6622-b01c-48c6-83b9-f2ca4e0bccf0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113280507975008719:28f4bb3e-b595-42de-b245-43104ad08e6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113313616455958933:46156bf8-6aa7-4aec-9d09-556399e010b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113380755594256419:24f0cb39-26d3-4c6f-aa2c-969af5b60a63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113559268943073470:8a83d078-83c4-4121-ae49-266de7f7df42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113644781960118583:b175b4cf-e4b7-4468-a71e-3ac8c888ee9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113645083492860351:283a90e5-62fa-45e5-bbb3-5a912e3329b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113645933313610223:ad813f6f-a882-4408-b037-6e724213aa52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113654251356311575:c4914f8e-8530-46cc-8808-0c8a111c17d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113685308348747845:a895c11f-a0bb-4344-8980-32b23ef49d05","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113799597260710362:29dd1673-5947-41ee-9dd1-f316a1630a8f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113901126840139821:9b358315-2d1b-4976-96e5-9b679cf8415d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113927459251077631:ed50edc3-e1db-4077-bbdf-c2e87faf07e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114357588125229335:abba0e76-1eff-4a41-ab3f-c96613a815ab","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":26,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":32},"count":32,"evidence_window":{"end":"2026-10-26","start":"2025-01-15"},"retrieval_snapshot":"2026-10-29T19:45:57.007072Z","timeline":[{"count":1,"week":"2025-W03"},{"count":1,"week":"2026-W11"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":23,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Jemperli"],"label":"dostarlimab","slug":"dostarlimab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Gastroesophageal adenocarcinoma","slug":"gastroesophageal-adenocarcinoma"},{"reason":"Unmapped registry condition: Gastric Adenocarcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"DEWI","aliases":["DEWI","DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study","Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study"],"brief_title":"DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Adenocarcinoma - GEJ","Gastric Adenocarcinoma"],"display_condition":"localized dMMR/MSI-H gastric/GEJ adenocarcinoma","display_interventions":[["dostarlimab"]],"enrollment":{"count":89,"type":"ESTIMATED"},"interventions":[{"name":"Dostarlimab","synonyms":["Jemperli"],"type":"DRUG"}],"nct_id":"NCT06059495","official_title":"Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2028-09-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Main initial cohort: To evaluate clinical complete response (cCR) at 1 year defined as the rate of patients who at 1 year from the start of therapy with dostarlimab are alive, were not operated for tumor resection, are free of disease progression (locoregional or metastases), have all negative biopsies, and show endoscopy downstaging stage 3 or 4 (endoscopic grade). Additional unfit cohort: To evaluate cCR at 1 year defined as the rate of patients who at 1 year from the start of therapy with dostarlimab are alive, are free of disease progression (locoregional or metastases), have all negative biopsies, and show endoscopy downstaging stage 3 or 4 (endoscopic grade).","measure":"Clinical complete response (cCR)","timeFrame":"At 1 year from the start of treatment with dostarlimab."}],"registered_date":{"date":"2023-09-28","type":"ACTUAL"},"registry_last_updated":"2026-08-26","registry_url":"https://clinicaltrials.gov/study/NCT06059495","short_name":"DEWI","short_name_basis":"registry_acronym","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","start_date":{"date":"2024-01-22","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"DEWI G-123","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-506102-39-00","type":"other"}],"study_type":"INTERVENTIONAL"}}}